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032 Is Cytogenetic Analysis Clinically Useful? An Analysis of 
101 Consecutive Cases of Benign and Malignant Bone and 
Soft Tissue Tumors of the Extremities
Robert M Henshaw1, Barry M Shmookler2, Martin M Malawer1
1Department of Orthopedic Oncology Washington Cancer Institute 
Washington Hospital Center, 2Department of Pathology Suburban 
Hospital
Objective: The purpose of this study was to evaluate the results
and clinical usefulness of cytogenetic analysis when routinely per-
formed for bone and soft tissue tumors.
Methods: 101  (51  malignant/50  benign)  consecutive  muscu-
loskeletal tumors surgically excised at our institution underwent
both cytogenetic analysis and traditional histologic evaluation. The
successful culture rate for the cytogenetic analysis was 86%. 57%
(26/46) of clearly malignant tumors successfully cultured demon-
strated  significant  clonal  abnormalities.  46%  (19/41)  of  benign
tumors  cultured  had  significant  cytogenetic  clonal  aberrations,
including 8 lipomas, 4 PVNS, 3 GCT, 2 fibromatosis, 1 chondrob-
lastoma and 1 schwannoma.
Results: Specific cytogenetic aberrations seen in various benign
tumors included chromosomal deletions, trisomies, translocations,
inversions, ring and marker formations, as well as dicentric and tel-
omeric associations. Increased cellular ploidy (more than 50 chro-
mosomes per cell) was demonstrated in 16/46 malignant and 1/41
benign  tumors.  Hyperploidy  was  highly  correlated  with  malig-
nancy (p<0.0004, chi squared analysis): the only “benign” tumor
was a multiply recurrent GCT demonstrating histologic changes
consistent  with  early  sarcomatous transformation.  As  expected,
cytogenetic  abnormalities  frequently  occurred  in  malignant
tumors. Surprisingly, almost half of the benign tumors tested had
significant clonal cytogenetic aberrations. Consistent findings of
extra chromosomes 5 and 7 in samples of PVNS strongly favor a
neoplastic origin for this condition.
Conclusion: Although  the  presence  or  absence  of  cytogenetic
aberrations cannot be used as a determinant of malignant poten-
tial, increased cellular  ploidy is highly indicative of malignancy.
Cytogenetic  analysis  can  be  useful  in  classifying  the  malignant
potential of recurrent and difficult to diagnose tumors of the mus-
culoskeletal system.
035 Molecular Genetic Characterization of Fusion Genes in 
Extraskeletal Myxoid Chondrosarcomas
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Objective: Extraskeletal myxoid chondrosarcoma (EMC) is a soft
tissue neoplasm cytogenetically characterized by t(9;22)(q22;q11-
12), generating a hybrid EWS/CHN gene, or a t(9;17)(q22;q11),
resulting in an RBP56/CHN chimera. Prior to the present study,
only 24 EMCs had been analyzed for the fusion transcripts, and
the expression of the native CHN gene had been examined in only
two cases. The aim of the present study was to characterize the
fusion transcript in 18  cases, and to correlate the findings with
karyotypic data.
Methods: The study was based on 18 surgical biopsies (17 from
primary lesions, one from a metastasis) from 18 patients (15 men,
three women; age at diagnosis 35–79 years) with EMC RT-PCR
was carried out for the detection of the EWS/CHN and RBP56/
CHN chimeric transcripts as well as for the expression of the full
length transcript of CHN and the two additional CHN transcript
variants: the 3´ -end truncated mRNA form and the Nor1b variant
with  the  alternative  5´ -untranslated  region.  Cytogenetic  analysis
was performed after short-term culturing.
Results: Chromosomal aberrations were detected in 16/17 cases
in our series; 13 with involvement of 9q22 and 22q12, and three
with rearrangements of 9q22 and 17q11. Fifteen cases carried an
EWS/CHN fusion transcript and three an RBP56/CHN transcript.
The most frequent EWS/CHN transcript (10 tumors), was fusion
of exon 12 of EWS with exon 3 of CHN (type 1), followed by
fusion of exon 13 of EWS with exon 3 of CHN (two cases; type 5).
In tumors with RBP56/CHN fusion, exon 6 of RBP56 was fused
to exon 3 of CHN. RT-PCR analysis of the native CHN showed
that it was expressed in 11 tumors, nine of which expressed both
the  long  and  short  3´   terminals,  with  and  without  the  ligand
domain, respectively.
Conclusion: From the  distribution  of  secondary chromosomal
abnormalities  and  previous  in  vitro  studies  of  the  EWS  and
RBP56 genes, one might predict that type of chimeric transcript
is of biologic significance. Indeed, in the present study, all four
patients who developed metastases had tumors with EWS/CHN
fusions.
042 Gene Expression in Lipoma, Hibernoma, and 
Liposarcoma
Keith M Skubitz, Edward C Cheng, Denis R Clohisy, Roby 
C Thompson, Carlos J Manivel, Amy P Skubitz
University of Minnesota
Objective: Malignant transformation is thought to be associated
with changes in the expression of a number of genes, and this alter-
ation in gene expression is felt to be critical to the development of
the malignant phenotype. In many cases, the progression to malig-
nant transformation is associated with the sequential acquisition of
multiple mutations. Sarcomas represent a diverse group of tumors
felt to be derived from cells of mesenchymal origin. Marked heter-
ogeneity exists in the biological behavior of sarcomas, even within
histologic subtypes of sarcomas. In an effort to better understand
the biology of sarcomas, we are examining gene expression using
the Affymetrix microarray technology.
Methods: In this study, the expression of ~60,000 genes/ESTs in
lipomas,  hibernomas, intra-muscular  lipomas,  and liposarcomas
was determined by Gene Logic. Differences  in gene expression
were quantified as the fold change in gene expression in lipomas
compared  with  hibernoma,  intra-muscular  lipoma,  atypical
lipomatous tumor, and liposarcoma.
Results: Nine  genes  were  expressed  greater  than  20  fold  (1
greater than 70 fold) more in lipomas than in lipomatosis, and 4
were expressed greater than 20 fold more in lipomatosis. Twelve
genes were expressed greater than 20 fold (3 greater than 80 fold)
more in lipoma than in hibernoma, and 13 were expressed greater
than 20 fold more in hibernoma. Interestingly, the thyroid hor-
mone responsive "spot 14" was more highly expressed in lipoma.
Eight genes were expressed greater than 50 fold (3 greater than
80 fold) more in lipoma than in intra-muscular lipoma. Seven
genes were expressed greater than 20 fold more in lipoma than in
liposarcoma, and 1 was expressed greater than 20 fold more in
liposarcoma.
Conclusion: We conclude that differences in gene expression may
help differentiate among subtypes of sarcomas, and may also yield
clues  to  the  pathophysiology  of  this  heterogeneous  group  of
tumors.S38 CTOS  abstracts
051 High Quality RNA Isolation from Chondrosarcoma; 
Application to cDNA Microarrays
H. J. Baelde1, A. M. Cleton-Jansen1, H. van Beerendonk1, 
M. Namba2, J. V. Bovee1, P. C. Hogendoorn1
1Department of Pathology, Leiden University Medical Center, 
2Department of Cell Biology, Institute of Molecular and Cellular 
Biology, Okayama University Medical School
Objective: High quality RNA isolation from cartilaginous tissue
is considered difficult due to relative low cellularity and the abun-
dance of extracellular matrix rich in glycosaminoglycans and col-
lagen. Given the growing interest and technical possibilities  to
study RNA expression at a high throughput level research on cer-
tain tumour types is hampered because of aforementioned char-
acteristics.
Methods: We present  a robust method using a combination of
two RNA isolation procedures that has been developed to obtain
high molecular weight RNA from fresh frozen and stored tissue of
normal  cartilage  and  cartilaginous  tumors.  Using  this  method
RNA was isolated from normal cartilage, peripheral and central
chondrosarcoma and from chondrosarcoma cell lines SW1353 and
OUMS-27. RNA quality was validated after electrophoresis and
staining with ethidium bromide. Subsequent conversion to cDNA
and labelling was followed by application to a Micromax Human
cDNA microarray system and fluorescence intensity was scanned
using an Affimetrix/GMS 418 scanner and analysed with a Gene-
Pix Pro 3.0 analysis program.
Results: The yields range from 0.1-0.5 mg RNA per mg tissue.
RNA samples from normal cartilage and from two chondrosarco-
mas isolated using this method were applied successfully in cDNA
microarray experiments. The number of genes that give interpret-
able results is in the range of what is expected when compared with
microarray results  obtained on  chondrosarcoma  cell  line  RNA.
Signal-to-noise ratios are good and differential expression between
tumor and normal cartilage  is  detectable  for a large number of
genes.
Conclusion: With  this  newly  developed  isolation  method  high
quality RNA can be obtained from low cellular tissue with high
extracellular matrix component. This RNA is of suitable quality for
subsequent cDNA microarray studies. These procedures can be
applied to other difficult tumor material as well.
076 In vitro Effectiveness of the Antineoplastic Drug 
Ecteinascidin-743 on Sensitive and Multidrug Resistant 
Osteosarcoma Cells
Katia Scotlandi1, Stefania Perdichizzi1, Maria Cristina Manara1, 
Massimo Serra1, Glynn Faircloth2, Maurizio D’Incalci3, Piero 
Picci1
1Istituti Ortopedici Rizzoli- Laboratorio di Ricerca Oncologica, 
2Pharma Mar USA, 3Istituto Di Ricerche Farmacologiche Mario Negri 
Department of Oncology
Objective: Ecteinascidin-743 (ET-743) is a highly promising anti-
tumor agent isolated from the marine tunicate Ecteinascidia tur-
binate  and  is  currently  under phase  II  clinical  investigation  in
Europe and the United States. Preclinical studies have shown that
ET-743 is active against a variety of tumor cell lines in vitro and
against several rodent tumors and human tumor xenografts in vivo
at low concentrations. In this study the antitumor activity of this
drug was evaluated against a panel of human osteosarcoma cell
lines characterized by different drug responsiveness.
Methods: A panel of 13, P-glycoprotein negative, human osteosa-
rcoma cell lines as well as 6 multidrug-resistant (MDR), P-glyco-
protein overexpressing, variants and two methotrexate- resistant
cell derivatives were analyzed in vitro to test the effectiveness of
ET-743 and its mechanisms of action. The degree of sensitivity
was expressed as the drug concentration resulting in 50% inhibi-
tion of growth (IC50) after 1 h or 96hr of continuous exposure to
ET-743. Cell cycle analysis and Bromodeoxyuridine labeling index
were obtained by flow cytometry after 24, 48 and 72 hr of drug
exposure.  Cell  death  induced  by  ET-743  was  evaluated  by
Annexin-test and morphologic analysis of apoptotic nuclei.
Results: 12/13  osteosarcoma  cell  lines  showed  an  IC50  value
ranging from 0.3 to 1 nM after a long-term exposure. These con-
centrations  are remarkably  low,  very  well  achievable  in  clinical
conditions and indicate that osteosarcoma is particularly sensitive
to ET-743. In comparable conditions, ET-743 was overall more
active  than  doxorubicin,  methotrexate  and  cisplatin,  the  three
leader drugs in the treatment of osteosarcoma. Furthermore, this
drug  was  found  to  be  completely  active  against  methotrexate-
resistant cells and significantly overcome MDR. Cell lines showing
up to 200-fold of resistance against doxorubicin, exhibit resistance
levels  to ET-743  lower than 10-fold.  Long-term  exposure  pro-
duced a higher extent of inhibition than a one-hour exposure, espe-
cially on MDR cells. At IC50 doses, ET-743 appeared to have a
cytostatic rather than a cytotoxic effect. Cells exposed to ET-743
progress through the cell cycle more slowly than untreated cells.
No induction of apoptosis was observed at these concentrations.
Conclusion: ET-743 appears to be very effective against osteosar-
coma cell lines, both against P-glycoprotein-negative and P-glyco-
protein overexpressing cells. This is particularly relevant since P-
glycoprotein is a major adverse prognostic factor in this neoplasm.
Therefore, ET-743 should be considered in the treatment of oste-
osarcoma patients.
080 Anchorage Independent Growth and Prolonged 
Survival of Primary Human Osteoblasts Over-Expressing 
the Met Receptors by Means of Transduction with Lentiviral 
Vectors
N Coltella1, S Patane’1, S Avnet3, M Olivero1, E Vigna2, 
L Naldini2, N Baldini3, M F Di Renzo1, R Ferracini1
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Objective: Osteoblast proliferation and differentiation is achieved
through  the  integrated  effects  of  several  signalling  molecules,
which switch on receptor-mediated events and activate gene tran-
scription. Each of the  molecules controlling critical  steps might
play a role in the genesis of osteoblast-derived tumours, including
receptor and non-receptor tyrosine kinases. Fragmentary data sug-
gest that among these receptors, those of the MET family might
also be involved in bone development and in osteoblast transfor-
mation. The MET oncogene-encoded tyrosine kinase receptor and
its ligand Hepatocyte Growth Factor (HGF) ordinarily constitute
a paracrine signalling system where cells of mesenchymal origin
produce the ligand, which binds to receptors expressed on cells of
epithelial origin. However, during mouse development HGF and
met are both expressed in tissues of mesenchymal origin and regu-
late migration of myoblast precursors. We previously showed that
the  MET receptor  is  aberrantly  over-expressed in  a number of
human osteosarcomas producing the ligand, suggesting that over-
expression with or without autocrine activation of MET receptors
might contribute to transformation of osteoprogenitor cells.
Methods: To  demonstrate  the  transforming  potential  of  the
MET oncogene in human osteoblasts, first we constructed an ex-
vivo model using primary 2D cultures of human osteoblasts with
stable expression of the MET receptors by means of transduction
with  Lentiviral  vectors.  Bicistronic  Lentiviral  vectors  carrying
either  wild-type  or  mutation-activated  (METY1235D)  MET
cDNA  followed  by  IRES  (internal  ribosomal  entry  site)  and
GFP-encoding sequences were used to transduce human osteob-
lasts. IRES sequences will ensure the concomitant expression of
the MET receptor and the reporter protein, allowing the detec-
tion and the selection in vitro and in vivo of transduced cells. TheCTOS  abstracts S39
human primary cultures transduced were from bone fragments
and  consisted  of  approximately  90%  cells  showing  osteoblast
phenotype.  The  latter  was  assessed  with  alkaline  phosphatase
assay and alizarine red staining of cells growing in differentiating
medium.
Results: Propagated  transduced  osteoblasts  showed  a  peculiar
morphology and behaviour: cells were spindle-shaped and small,
did not show cell  contact inhibition  in monolayer cultures  and
form colonies in soft agar. Different levels of MET expression were
detectable in osteoblast clones and correlated with the ability of the
cells to form colonies in agar. MET expressing osteoblasts grew for
more than 30 passages in culture, corresponding to approximately
150 days. After 100 days the expression of the transgene declined
but the level of MET receptor expression remained elevated. Most
of the MET receptor stably over-expressed in long-term cultures
was due to activation of the endogenous MET gene transcription.
Conclusion: These data show that over-expression of the MET
oncogene in human  primary osteoblast  due either  to  transgene
transduction or reactivation of endogenous MET expression con-
fers to cells of mesenchymal origin the ability to grow in an anchor-
age independent fashion and to survive longer than the parental
line. Further experiments will assess if the prolonged survival of
osteoblasts depends on a block of apoptosis or to inactivation of
regulated Rb control or to a telomer lengthening activity.
086 Expression of Osteopontin and HGF/SF-Met in Adult 
Soft Tissue Sarcoma
Stewart C. Rorke1, Vivien H. Bramwell1, Ann F. Chambers1, Alan 
B. Tuck2, Larry Stitt3
1London Regional Cancer Centre, 2London Health Sciences Centre, 
3University of Western Ontario
Objective: (1) To determine the range of expression of osteopon-
tin (OPN) (a secreted phosphoprotein associated with malignant
transformation) and Met (an oncogene encoded transmembrane
kinase) in adult soft tissue sarcoma (ASTS). (2) To determine if
expression of these markers is associated with clinical outcome var-
iables.
Methods: Thirty-three tissue samples from ASTS were obtained
from a cohort of patients registered in the Canadian Soft Tissue
Sarcoma Tumor Bank/Correlative Clinical Data Base. OPN and
Met expression were determined by semiquantitative immunohis-
tochemistry. Results were expressed as a total score derived from a
combination of intensity (0-3) and proportion (0-5) of staining, for
a potential total out of 8.
Results: Included in the cohort were 8 superficial and 27 deep
tumours, with a median maximum diameter of 9 cm. There were
33 primary tumours and 1 local recurrence. Most common among
a wide range of histologies  were malignant fibrous histiocytoma
(9), liposarcoma (7), and leiomyosarcoma (6). Number of patients
with grades 1, 2, 3-4 were 5, 13, and 12 respectively (not available
(N/A) in 3 patients). UICC clinical stage (at the time of sample
submission):I(6),  II  (14),  III  (6),  IV  (3),  N/A  (4).  Surgeries
included: amputation (2), local marginal resection (22), and wide
resection (9). Adjuvant chemotherapy and radiation was given in 4
and 15 patients respectively. Two patients received neoadjuvant
chemotherapy. Median follow-up time was 40 months (range 2–84
months) and the 2-year overall survival was 69%. Mean OPN and
Met scores were 2.8 and 1.4 respectively. Scores ranged from 0 to
7 in OPN and 0 to 6 in Met, with standard deviations of 2.2 and
2.0 respectively. With respect to OPN score, Spearman correlation
coefficients for stage and grade were 0.479 (p=0.009) and 0.500
(p=0.005)  respectively,  indicating  strong  positive  associations.
Univariable Cox regression analysis showed that increasing OPN
levels predict decreased disease-free survival (DFS) (Hazard ratio
(HR) = 1.55, (95% CI:1.15-2.10), p=0.003). Similarly, OPN was
significantly  associated  with  decreased  overall  survival
(OS)(HR=1.31,  (95%  CI: 1.006-1.714),  p=0.045).  Met  scores
were not significantly associated with outcome.
Conclusion: In this small retrospective analysis of an ASTS cohort:
(1) Increased OPN expression (determined immunohistochemi-
cally) was associated with decreased DFS and OS. (2) Level of Met
expression was not significantly associated with outcome. There
are many potential pitfalls in analysis of marker expression in small
inhomogeneous cohorts of patients, and these findings need to be
explored in a larger series of ASTS cases.
089 Fusion of the ALK Gene to the Clathrin Heavy Chain 
Gene, CLTC, in Inflammatory Myofibroblastic Tumor
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Hill2, William Lydiatt1, Man Yee Lui3, Gisele WB Colleoni3, 
Cristina R Antonescu3, Marc Ladanyi3, Stephan W Morris2
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Medical Center, 2Departments of Pathology and/or Hematology/
Oncology, St. Jude Children’s Research Hospital, 3Department of 
Pathology, Memorial Sloan-Kettering Cancer Center
Objective: Recently, clonal mutations [fusion of the tropomyosin
(TPM) N-terminal coiled-coil domains to the ALK C-terminal-
kinase domain] have been detected in a subset of inflammatory
myofibroblastic tumors (IMTs) supporting a neoplastic pathogen-
esis  for this biologically  controversial entity (Am J Pathol 2000;
157:377). The ALK gene is localized to chromosomal band 2p23
and the TPM3 and TPM4 genes are localized to 1q22-23  and
19p13.1 respectively. In the current study, cytogenetic analysis of
an IMT revealed a 2;17 translocation [t(2;17)(p23;q23)]. Because
17q23 is not the chromosomal locus of either TPM3 or TPM4,
our objective was to determine the ALK fusion gene partner in this
case and in an additional IMT not exhibiting a TPM3-ALK or
TPM4-ALK fusion gene transcript.
Methods: Case 1 was obtained from an IMT of the neck of a 3-
year-old female and Case 2, an IMT of the pelvis of a 37-year-old
male. Conventional cytogenetic analysis was performed on a ster-
ile, representative tissue sample from Case 1. Material suitable for
cytogenetic analysis was not available for Case 2. Fluorescence in
situ hybridization (FISH) studies employing 2p23 (ALK) break-
point spanning and flanking probes (Vysis, Downers Grove, IL)
were executed on metaphase preparations of Case 1 and on cyto-
logic  touch  preparations  of  both  cases.  Rapid  amplification  of
cDNA ends (RACE) studies were performed on Case 1 using the
5’ RACE system from Gibco BRL (Rockville, MD). The products
were analyzed on agarose gels.  Sharp product bands were sub-
jected to direct sequencing, whereas non-discrete products were
cloned and multiple independent clones were sequenced. Follow-
ing RACE analyses, heminested reverse transcriptase – polymerase
chain reaction (RT-PCR) studies were performed to confirm the
presence of a CLTC-ALK fusion gene in both cases. The identi-
fied product bands were directly sequenced.
Results: Case 1 exhibited the following: 46,XX,t(2;17)(p23;q23),
add(16)(q24)[5]/ 92,idem x2[1]/46,XX[4]. Case 1 metaphase cell
FISH confirmed the presence of a 2;17 translocation involving the
ALK locus. Cases 1 and 2 interphase cell FISH revealed a split of
one set of the two-color probe signals, indicating a disruption of
the 2p23 breakpoint (ALK) on one chromosome 2 homologue in
52%  and  46%  of  the  cells,  respectively.  5’  RACE  of  Case  1
revealed  an  ALK  fusion  with  the  clathrin  heavy  chain  gene
(CLTC) localized to 17q23. This CLTC-ALK fusion incorporates
1,634 residues of the 1,675-aa clathrin heavy chain. Heminested
RT-PCR confirmed the presence of a CLTC-ALK  fusion gene
product in Case 1 and demonstrated the identical fusion product
in Case 2. The ALK and CLTC breakpoints in these IMTs were
identical to those recently reported in CLTC-ALK fusions in ana-
plastic large cell lymphoma (ALCL), (Blood 2000; 95:3204).S40 CTOS  abstracts
Conclusion: The CLTC-ALK fusion oncogene represents a novel
mechanism of ALK activation in IMT and demonstrates that, sim-
ilar to ALCL, the fusion partners of the ALK gene in IMT are
diverse. ALK protein expression is an independent predictor of
survival and serves as a useful biological marker of a specific dis-
ease entity within the spectrum of ALCL. Additional studies are
warranted to determine whether ALK protein expression is like-
wise associated with specific clinicopathological traits in IMT.
090 Evaluation of Ezrin, a Novel Determinant for Metastasis 
in Osteosarcoma: A Comparative Approach
Chand Khanna1, Seuli Bose1, Sung-Hyeok Hong1, Ryan 
Cassaday1, Stephen Hewitt2, Richard Gorlick3, Lee Helman1
1Pediatric Oncology Branch, National Cancer Institute, National 
Institutes of Health, 2Laboratory of Pathology Tissue Array Research 
Project, National Cancer Institute, National Institutes of Health, 
3Memorial Sloan-Kettering
Objective: To evaluate the importance and relevance of ezrin in
the biology of osteosarcoma metastasis using a cross species com-
parative approach (murine, canine, and human). This approach
allows tissues from children and pet dogs with naturally occurring
osteosarcoma to add relevance to genomics data generated from
our in vitro and in vivo metastasis models.
Methods: Using cDNA microarrays and a metastasis based meth-
odology for array evaluation we have defined 11 genes (out of 3899
cDNAs) most likely to explain differences in the behavior of a high
(K7M2) and low (K12) metastatic model of murine osteosarcoma.
Ezrin,  a  gene  not  previously  described  in  osteosarcoma,  was
selected for further evaluation based on its pivotal role in linking
the actin cytoskeleton to the cell membrane. Evaluation of ezrin in
the  murine  osteosarcoma  models  included  Northern,  Western,
and immunocytochemistry. The function of ezrin was studied by
generating K7M2 cells with low expression of ezrin through the
stable transfection of these cells with a full-length antisense ezrin
construct. Preliminary evaluation of ezrin function included tran-
swell® matrigel invasion and heterotypic adhesion assays. The rel-
evance  of  ezrin  in  osteosarcoma  was  examined  in  a  canine
osteosarcoma tissue  array consisting  of 75  canine osteosarcoma
primary tumors and 11 pulmonary metastases. The expression of
ezrin  in  human  osteosarcoma  was  examined  by  immunohisto-
chemistry.
Results: Differential expression of ezrin between K7M2 and K12
models by Northern was concordant with microarray (2.9:1). Evi-
dence  for  differential  post-transcriptional regulation  came  from
Western analysis where an 8.0 fold increase in ezrin protein was
seen in highly  metastatic  K7M2 compared to poorly metastatic
K12.  Immunostaining was  consistent  with  Western  results  and
supported greater membrane (active) localization of ezrin in the
more aggressive K7M2 cells. Stable antisense ezrin transfection of
the K7M2 cells resulted in clones with low (K7M2-AS1.42 and
K7M2-AS1.56) and intermediate (K7M2-AS13) ezrin protein lev-
els. Functional studies compared the antisense ezrin transfectants
with  an  empty  vector  control  (K7M2-EV)  and  the  wild-type
K7M2  and  K12  cells.  K7M2-AS1.42  and  K7M2-AS1.56  had
notably  decreased  invasiveness  through  matrigel  compared  to
K7M2-AS13  and  the  K7M2-EV  control  (p=0.06  and  p=0.05
respectively).  K7M2-AS1.42,  K7M2-AS1.56  and  K7M2-AS13
had heterotypic adherence kinetics similar  to the less metastatic
K12 cells. Immunohistochemistry for ezrin using the canine oste-
osarcoma  tissue  array  demonstrated  high  ezrin  expression  in
100%(11/11) of pulmonary metastases compared to 30% (42/70)
of primary tumors (p=0.0001). Furthermore dogs without primary
tumor ezrin had longer median survival than dogs with ezrin stain-
ing (Ezrin(-) 280 days vs Ezrin(+) 136 days; p=0.10). In frozen
pediatric osteosarcoma ezrin expression was seen in 8/12 tissues by
immunohistochemistry. High intensity staining was seen in 0/7 pri-
mary tumors and 2/5 pulmonary metastases.
Conclusion: This comparative approach has demonstrated the rel-
evance and potential importance of ezrin in the biology of osteosa-
rcoma metastasis. Preliminary results suggest a role of ezrin during
cellular  invasion and heterotypic  adhesion. Ongoing efforts  will
define the role of ezrin in vivo and through all steps of the meta-
static cascade. Staining of a recently constructed pediatric osteosa-
rcoma  tissue  array  has  been  completed  and  will  define  the
relevance of ezrin in pediatric osteosarcoma.
091 Chromosome 9 Alterations and P16 Expression in 
Central Chondrosarcomas
J. V. Bovee1, D. Federov1, H. van Beerendonk1, A. H. Taminiau4, 
R. Sciot2, M. Debiec-Rychter3, A. M. Cleton-Jansen1, 
P. C. Hogendoorn1
1Department of Pathology, Leiden University Medical Center, 
2Department of Pathology, Leuven University, 3Center for Human 
Genetics, Leuven University, 4Department of Orthopedic Surgery, 
Leiden University Medical Center
Objective: Chondrosarcomas  are  characterized  by  neoplastic
growth of cartilage forming tumor cells. The majority (75%) arise
centrally, in the medullar cavity, while a minority develop periph-
erally  secondary to  an  osteochondroma.  We  previously  investi-
gated  DNA-ploidy  and  loss  of  heterozygosity  (LOH)  at  loci
harboring the EXT-genes (implicated in hereditary multiple exos-
toses), the EXT-like genes, and at 9p21, 13q14, 17p13 and chro-
mosome 10 in 12 central chondrosarcomas. Only 3 cases exhibited
LOH, with 9p21 involved in all three. At 9p21 the p16 tumour
suppressor gene is located. Our goal was to further investigate this
chromosomal region and the expression of the candidate gene p16.
Methods: LOH analysis was performed in the region of p16 on 38
additional cases. Cytogenetic analysis was performed on 16 central
chondrosarcomas. p16 immunohistochemistry was performed on
formalin-fixed paraffin-embedded tissue of 84 cases to estimate the
effect of 9p21 alterations on p16 protein expression.
Results: Of 38 central chondrosarcomas 12 (32%) revealed LOH
in the 9p21 region. Seven central chondrosarcomas demonstrated
an abnormal karyotype, 5 of which involved chromosome 9. Three
central tumours showed involvement of the 9p12-22 region includ-
ing t(9;10)(p22;q22),  add(9)(p21) and add(9)(p12). For two of
them paraffin blocks were available revealing absence of p16 protein
expression. Two tumours with -9 and del(9)(q12) demonstrated
p16 protein expression. In 3 chondrosarcomas demonstrating LOH
at 9p21, p16 protein expression was absent, while in 6 out of 9 cen-
tral chondrosarcomas without LOH at 9p21, p16 protein expres-
sion could be demonstrated. In general loss of expression of p16 by
immunohistochemistry was found in 18 % of the cases.
Conclusion: The involvement of genes located at chromosome 9,
especially the 9p12-22 region, is suggested both by the LOH results,
p16 immunohistochemistry as well as the cytogenetic studies. Since
9p21  alterations  are associated with  the  absence  of p16  protein
expression, this suggests an important role for the p16 tumour sup-
pressor gene in the development of central chondrosarcomas.
100 Classification of Gene Expression Profiles in Adult Soft 
Tissue Sarcoma Using Oligonucleotide Array Analysis
Neil H Segal, Robert G Maki, Alex Smith, Elyn Riedel, Katherine 
S Panageas, Cristina R Antonescu, Jonathan J Lewis, Murray 
F Brennan, Alan N Houghton, Carlos Cordon-Cardo
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Objective: Adult soft tissue sarcoma (STS) represents a diverse
group of neoplastic diseases that are grouped together because of
shared biological characteristics  and clinical responses [1]. ThisCTOS  abstracts S41
study was undertaken to identify the differential gene expression
profile obtained from various histological categories of STS. Large
scale gene expression data could be used to validate the current
classification  system  for  STS,  investigate  an  alternative  gene
expression  based classification system,  and furthermore identify
genes  that  differentiate  between tumors  of varying clinical  out-
come. Gene expression profiles may offer more information than
classic  morphology  and  provide  an  alternative  to  morphology-
based tumor classification systems.
Methods: Total RNA was isolated from 30 cases of high grade
STS, including leiomyosarcoma, fibrosarcoma, liposarcoma, syn-
ovial sarcoma, GIST, MFH and clear cell sarcoma. cRNA was pre-
pared according to the Affymetrix® protocol and hybridized to the
U95A GeneChip® array. An average difference (AD) value was
generated that corresponds to the level of gene expression. Expres-
sion  data  was  scaled  to  2500  using  the  96%  mean-centered
method. Absent calls and negative values were set to an overall
average background value. Gene lists by tumor type were gener-
ated by ranking of  F-statistic  values. Multi-dimensional  scaling
was also applied to the original data in an unsupervised analysis to
demonstrate inherent similarity of STS tumors.
Results: Expression data was determined for ~12 500 genes previ-
ously reported in terms of function or disease association (Affyme-
trix®).  Individual  tumors  showed  distinct  patterns  of  gene
expression. The top 100 genes were selected by rank of F-statistic
to discriminate the test group of STS. 21 genes were shown to dis-
criminate synovial sarcoma. PRAME, a cancer-testis antigen rec-
ognized by autologous T cells in melanoma [2], was shown to be
expressed in synovial sarcoma and to a lesser extent in fibrosar-
coma. 40 genes were shown to discriminate GIST, including c-kit.
39  genes were shown to discriminate  clear cell  sarcoma. Using
unsupervised multidimensional scaling, across ~10 500 genes, syn-
ovial sarcoma, GIST and clear cell sarcomas emerge as distinct
clusters. The remaining specimens did not appear to separate into
histological or distinct genetic groups (figure).
Conclusion: We identified several potentially important genes in
the diagnosis and biology of STS. We have shown that synovial
sarcoma,  GIST  and  clear  cell  sarcoma  are  genetically  distinct
within themselves and relative to the more homogeneous group of
high grade leiomyosarcoma, fibrosarcoma and MFH. The liposar-
coma group is as yet inconclusive, being comprised of dedifferen-
tiated  and pleomorphic  liposarcomas.  MFH  and fibrosarcomas
grouped together. These data indicate that MFH may represent
pleomorphic fibroblastic tumors rather than tumors with a distinct
histiocytic histogenesis. GISTs, previously considered as gastro-
intestinal leiomyosarcomas, stand out as a separate group charac-
terized by abnormalities in c-kit. Research in progress aims to iden-
tify gene lists that may discriminate between the latter group of
tumors, and to characterize selected transcripts that may provide
insight into the pathology and clinical behavior of STS. 1. Mann,
G.B. et al. Aust N Z J Surg, 1999; 69(5): 336-43. 2. Ikeda, H., et al.
Immunity, 1997; 6(2): 199-208.
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Objective: Synovial  sarcomas  consistently  contain  a  specific
t(X;18)(p11;q11),  which  represents  either  of  two  gene  fusions,
SYT-SSX1 or SYT-SSX2. Previous studies have suggested that
patients with SYT-SSX2 tumors do better than those with SYT-
SSX1 tumors, but the study groups were relatively small.
Methods: To address this  issue  more  definitively,  we collected
data on SYT-SSX fusion type, pathology, and clinical course in a
retrospective multi-institutional  study of 243 patients (of whom
44% were under age 30 – age range 6-82) with synovial sarcoma,
of  which  89%  were  localized  at  presentation  and  67%  were
extremity primaries.
Results: SYT-SSX1 and SYT-SSX2 fusions were detected in 147
tumors (61%) and 91 tumors (37%), respectively. There were 180
(74%) monophasic and 61 (25%) biphasic tumors. The previously
observed association of fusion type and histology was confirmed in
this  series  (n=236; p<0.001).  Of  236  cases  with  data  for  both
fusion type and histologic type, there  were only 3 SYT-SSX2+
biphasic tumors. There was also a statistically significant associa-
tion of fusion type and patient sex  (n=232; p=0.03); the male-
female ratio of SYT-SSX1 cases was 1:1, whereas for SYT-SSX2
cases, it was close to 1:2. There was a trend for patients with SYT-
SSX1  +  tumors  to  present  more  often  with  metastatic  disease
(n=231; p=0.05). There was no significant association of fusion
type with patient age and size or site (axial vs peripheral) of the pri-
mary tumor. Median and 5  year overall survivals for the SYT-
SSX1 and SYT-SSX2 groups were 6.1 years and 53%, and 13.7
years  and  73%,  respectively.  Overall  survival  was  significantly
better among SYT-SSX2+ cases (n=228; p=0.03), among cases
localized  at  diagnosis  (n=231;  p<0.0001),  and  among  patients
with primary tumors less than 5 cm in greatest dimension (n=200;
p=0.01). Age, sex, histologic type, and axial vs peripheral primary
site had no impact on overall survival. The impact of fusion type
on survival remained significant when stratified for primary tumor
size (n=198; p=0.03) but was no longer significant when stratified
for disease status at presentation (n=226; p= 0.16). Cox regression
identified  disease  status  (p<0.0001)  and  primary  tumor  size
(p=0.04) as the only factors independently predictive  of overall
survival in the subset of 160 patients with information on all fac-
tors. Within the subset of patients with localized disease at diagno-
sis (n=202), the median and 5-year survival for the SYT-SSX1 and
the SYT-SSX2 groups were 9.2 years and 61%, vs 13.7 years and
77%,  respectively.  Patients  whose  tumors  contained  the  SYT-
SSX2 fusion (n=202, p=0.08) or were smaller (n=174, p=0.12)
showed a trend toward better survival by log rank test, whereas
tumor histology had no impact (p=0.8). By Cox regression analysis
considering all factors, SYT-SSX fusion type emerged as the only
independent significant factor (p=0.044) for overall survival within
the subset of 133 patients with localized disease at diagnosis who
had information on all factors.
Conclusion: Overall, SYT-SSX fusion type appears to exert part
of its impact on prognosis prior to presentation, through its associ-
ation with stage at presentation, which remains the strongest prog-
nostic factor in all patients.
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Objective: In many cancers, tumors harboring mutations of the
p53 gene have a more aggressive clinical course or are more likely
to be from advanced disease. To address the role of p53 mutations
in osteosarcoma development and progression we analyzed 247
primary localized osteosarcomas and 25 osteosarcomas that were
metastatic at diagnosis. The group included 27 matched biopsy-
resection and 21 biopsy-metastasis paired specimens.S42 CTOS  abstracts
Methods: Tumor specimens and corresponding clinical data were
obtained from 272 patients with biopsy proven high-grade osteosa-
rcoma  of  the  extremity  from  six  tertiary  care  institutions.  The
nature and location of p53 mutations (exons 4 through 10) were
examined by PCR-SSCP (single  strand conformation polymor-
phism), confirmed by direct DNA sequencing, and compared with
clinicopathologic factors identifiable at the time of diagnosis. The
prognostic significance of p53 mutation status was investigated in
a cohort  of  202  patients  with  classical  osteosarcoma who  were
treated with chemotherapy and local tumor resection and followed
prospectively. Survival analysis of p53 gene status was by the log-
rank test and Cox proportional hazards model.
Results: In the entire group of 272 patients, the overall frequency
of p53 mutations was 22% (60/272) with 13 of the 60 mutations
located in exons 4 or 10. A similar proportion of localized osteosa-
rcomas had alterations of the p53 gene (55/247, 22.3%) compared
to tumors from patients with metastases at diagnosis (5/25, 20%;
p=0.96). Tumors from patients with localized osteosarcomas and
those with metastases at diagnosis also exhibited equal proportions
of missense (32/247, 13% vs. 3/25, 12%) and nonsense (23/247,
9% vs. 2/25, 8%) mutations respectively. Patients with p53 mis-
sense mutations were older than those with nonsense alterations or
a wild-type gene (p=0.01). Tumor site (p=0.006) and tumor size
(p=0.002) were the only factors associated with systemic disease
status at diagnosis, but neither was related to p53 status. Examina-
tion of paired biopsy-resection and biopsy-metastasis  specimens
revealed that the p53 status was concordant between the biopsy
and later tumor specimens in all cases. In the prospective cohort of
202 patients with localized osteosarcoma, there was no significant
association between the presence of a p53 mutation and develop-
ment of systemic disease recurrence by either univariate (p=0.18)
or multivariate (p=0.16) analysis.
Conclusion: P53  mutation status  was concordant for all  paired
tumor specimens, and did not differentiate between patients pre-
senting with a localized osteosarcoma and those with metastases at
diagnosis. These results indicate that p53 mutations are not late
events  in  osteosarcoma  tumor  progression  as  they  are  evident
before the development of metastases. Even for patients presenting
with a localized osteosarcoma, p53 status was not a predictor of
disease outcome. New molecular prognostic features of osteosar-
coma are needed to improve patient stratification and treatment.
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Objective: Malignant Fibrous Histiocytomas (MFH) are group of
malignant mesenchymal tumors that present a dilemma for clinical
management. Current staging  systems,  based on morphological
tumor characteristics cannot accurately classify or predict an indi-
vidual patient’s risk for eventual metastases. We hypothesize that
characterization of gene expression patterns of MFH will improve
classification  of these  tumors.  To  identify  clinically  meaningful
patterns of gene expression in MFH we are taking advantage of a
soft tissue sarcoma tumor bank and a high-throughput microarray
technology which is capable of profiling gene expression patterns
of tens of thousand genes in a single experiment.
Methods: Tumor  specimens  were  obtained  from  37  patients
with  MFH who did not receive preoperative chemotherapy or
radiotherapy. Total RNA was extracted with the RNeasy purifi-
cation  kit  (Qiagen).  5m g  of  tumor  and  reference  RNA  were
labeled with Cy3-dCTP and Cy5-dCTP fluorescent tags respec-
tively, using an indirect labeling method and hybridized simulta-
neously  to  19200  cDNA  microarray  chips.  Reproducibility
experiments  were performed  for each  tumor/reference pair, in
which the tumor and reference sample were re-assessed using the
reciprocal fluorescent tag. The standard reference sample  (i.e.
control) consisted of a pool of RNA from 11 different tumor cell
lines.  Following  hybridization,  arrays  were  scanned  using  an
Axon scanner and spots were quantitated with GenePix 3.0 anal-
ysis software.
Results: Before using the limited RNA from these specimens, we
performed pilot studies to evaluate the feasibility of the technology
on a larger scale using cDNA microarrays containing 1700  and
19200 sequence verified human cDNAs. We performed 10 self test
experiments in which each pool of control RNA was split, labeled
by Cy3 and Cy5 and simultaneously hybridized to the same 1700
cDNA array. The analysis of scatter plots for these experiments
showed the consistency of the labeling and hybridization proce-
dures, as evidenced by high correlation coefficients (R2 = 0.92-
0.97). We also analyzed 5 MFH cases using 1700 cDNA chips. To
allow for comparison of results between tumors each tumor was
analyzed using the same control sample. Background subtracted
signal intensities between the two fluorescent images were normal-
ized by applying the median of Cy3/Cy5 log ratio as a normaliza-
tion factor overall and by subarray for each microarray experiment.
Comparison  of  the  data  across  10  experiments  for  5  tumors
showed that 12 genes had consistently high ratios and 17 genes had
consistently low ratios. We further investigated 7 low grade and 8
high grade MFH tumors by using arrays with 19200 genes. Biosta-
tistical modeling is being used to detect clusters of genes that may
distinguish MFH tumors.
Conclusion: We have been able to devise a system that may distin-
guish the variation in gene expression of 19200 genes in low grade
and high grade MFH tumors. Statistical approaches will enable us
to  detect  sets  of  genes  that  are  differentially  expressed  in  high
versus low grade tumors. Further evaluation will allow us to deter-
mine their potential use in differential diagnosis and early detec-
tion of MFH.
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Objective: Enchondromas  are  common  benign  cartilage
tumours. When they occur in multiple locations in enchondroma-
tosis (Ollier’s disease), the risk of skeletal deformity and of malig-
nant  change  to  chondrosarcoma  is  high.  Enchondromas  are
usually in close proximity to, or in continuity with, growth plate
cartilage. Consequently, they may result from abnormal regula-
tion of proliferation and terminal differentiation of chondrocytes
in the adjoining growth plate. In normal growth plates, differenti-
ation of proliferating chondrocytes to post-mitotic hypertrophic
chondrocytes is regulated in part by a tightly coupled signalling
relay  involving  Indian  hedgehog  (IHH)  Parathyroid  hormone
related protein (PTHrP). We speculated that inappropriate regu-
lation of the IHH-PTHrP pathway contributes to the genesis of
enchondromas.
Methods: We  utilized  semiquantitative  RT-PCR  and  Western
blot analysis to test for expression of IHH-PTHrP pathway mem-
bers, and a short term primary cartilage tumour explant culture
system to test the functional effects of Hedgehog and PTHrP ago-
nists and antagonist in vitro. Proliferation was assessed by tritiated
thymidine uptake, and differentiation by type X collagen expres-
sion  level  (an exclusive  product  of  hypertrophic chondrocytes).
Single  strand conformation polymorphism  analysis and manual
sequencing were used for mutational screening. In vitro CyclicCTOS  abstracts S43
adenosine  monophosphate  (cAMP)  and  Inositol  triphosphate
(IP3) assays were performed using wild type (WT) and mutant
constructs  generated  via  site-directed  mutagenesis,  which  were
transiently transfected into COS-7 cells and embryonic stem cells
lacking native  Type 1  PTH/PTHrP receptor (PTHR1). Trans-
genic mice were generated by pronuclear microinjection of WT or
mutant PTHR1 cDNA flanked by the regulatory elements of Type
II collagen (ColII) for expression in cartilage. Genomic DNA was
extracted from tails and screened by Southern blot for integration
of the transgene. Paraffin embedded sections from transgenic mice
were  used  for  immunohistochemistry,  safranin-O  histology  and
tartrate resistant acid phosphatase (TRAP) staining.
Results: We showed that key IHH-PTHrP pathway members are
expressed in enchondromas and chondrosarcomas. The IHH and
PTHrP signalling pathways were functional, but the feedback loop
regulating IHH was dysregulated in these lesions. We identified a
mutant  PTHR1  in  two  patients  with  enchondromatosis.  This
mutant lowered baseline cAMP level and abolished IP3 accumula-
tion in vitro. Expression of the mutant, but not WT, PTHR1 in the
growth plates of transgenic mice resulted in the appearance of mul-
tiple enchondromas. These enchondromas were likely caused by
abnormal proliferation and not abnormal resorption, since growth
plate zonal architecture was altered, but the number of TRAP pos-
itive cells, which resorb the growth plate, were not.
Conclusion: These data suggest that enchondromas can arise due
to abnormal growth plate development. In particular, some cases
of enchondromatosis are likely caused by a mutant PTHR1. The
persistence of growth plate tissue in the form of enchondromas
beyond adolescence, when growth plate tissue has normally disap-
peared in humans, may allow accumulation of secondary genetic
events which cause chondrosarcoma to arise within a preexisting
enchondroma. Agents that block IHH-PTHrP signalling might be
of therapeutic benefit in preventing the deleterious consequences
of enchondromas.